Biofarm, one of the most important drug manufacturers in Romania, estimates a turnover of 325 million RON for this year, which represents a 17 percent increase compared to 2022. In addition, Biofarm estimates a six percent higher profit for 2023 compared to last year.

“In 2022, the pharmaceutical market faced significant challenges due to rising energy and raw material prices as well as a lack of products to treat cold and flu symptoms. Even under these conditions we have performed very well and managed to secure the necessary stocks and contribute to covering the shortage of cold and flu products through efficient management of production and distribution. For 2023, we aim to strengthen our position in the market and we have set ourselves targets of constant growth in turnover at an accelerated pace as a result of portfolio development through line extensions or new product launches”, said Catalin Vicol, Biofarm CEO.

Biofarm has invested more than 44 million euros so far in one of the most modern drug factories in Romania, which covers an area of more than 10,000 square meters and has four production streams, specializing in tablets, film-coated tablets, dragees, soft capsules, solutions, and syrups.